The contribution of the innate immune system to inflammatory bowel disease (IBD) is under intensive investigation. While research in animal models has demonstrated that type I interferons (IFN-Is) protect from IBD, studies of patients with IBD have produced conflicting results concerning the therapeutic potential of IFN-Is. Now a team of researchers based in Vienna with a contribution of the LBI-CR have resolved this issue.
Recently Emilio Casanova and co-workers published their findings on growth hormone resistance in liver disease. Their work has now been released online by the Journal "Hepatology" and the findings were featured in Nature Reviews Gastroenterology by Claire Greenhill:
Together with the company Tissuegnostics, the pathologist Lukas Kenner and his colleagues have developed a software that is able to identify cancer cells in tissue sections and demonstrate the presence of specific biomarkers on cells. "The recently developed software offers, for the first time, the option of eliminating the so-called inter-observer-variability, which is the systematic variability of judgement among different observers," chief investigators Lukas Kenner and Helmut Dolznig explain.
The European Research Initiative on Anaplastic lymphoma kinase (ALK)-related malignancies (ERIA) celebrated the twentieth anniversary of the discovery of ALK at its annual meeting in Monza on June 20-21, 2014. The meeting was attended by Prof Tom Look (Dana Faber Institute, Harvard), the co-discoverer of the fusion gene NPM-ALK in lymphomas, and Dr. Robert Ghelfi (Pfizer), who developed the first compound to inhibit ALK, crizotinib.
The annual review meeting of the LBI-CR was held on June 15 - 17, 2014. The researchers presented the recent scientific ouput to the scientific advisors and partners, who voiced their unanimous satisfaction about the quality of the research activities at the institute. Moreover, the scientific advisors appeared impressed with recent organisational developments, which include the appointment of the junior group leader Florian Grebien to the institute and the integration of three researchers into the partner universisties as endowed professors.
The chairman of the scientific advisory board, Tom Look (Dana Faber Institute, Harvard Medical School) discovered the proto-oncogene ALK, which is increasingly recognised as an important driver of cancer in a wide variety of tumors. He gave an interview to the daily "Der Standard", which is available below in German only.
Mag. Michael Krassnitzer reported in the current issue of "Clinicum" about the research at the Ludwig Boltzmann Institut for Cancer Research.
Mag. Claudia Lingner, DI Josef Pröll, Prof. Richard Moriggl supported by staff of the LBI-CR hosted Mag. Georg Kapsch, the president of the Federation of Austrian Industries on June 2, 2014. Mag. Kapsch showed himself impressed by the possibilities of modern cancer research and showed particular interest for the potential of novel cancer models generated through genetic modification.
The research team of Lukas Kenner received the prestigious Novartis-Award of the German Society of Pathology (Deutschen Gesellschaft für Pathologie e.V., DGP) for their outstanding work entitled „PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas" published in Nature Medicine. Former co-worker Dr. Laimer received the award personally on June 12 in Berlin during the 98th annual meeting of the DGP.
Since 2005 the LBI-CR has evolved into one of Austria's internationally visible scientific institutions in cancer research. With the creation of three endowed professorships by the Medical University Vienna and the University for Veterinary Medicine, Vienna in cooperation with the LBG the integration of the established center of excellence into the Austrian scientific community is under way.